Report on Polish Biotech & Pharma
|
|
- Jewel White
- 7 years ago
- Views:
Transcription
1 Report on Polish Biotech & Pharma
2 Polish Biotech & Pharma is a Sector Promotion Programme under the project system implemented by the Polish Ministry of Economy entitled: The Promotion of Polish Economy in International Markets, Sub-measure of the Operational Programme Innovative Economy (OPIE). The programme aims to support individual entrepreneurs in a variety of promotional events and international expansion, which contributes to building a strong brand for the Polish biotech and pharmaceutical industry. It includes diverse forms of promotion, such as participation in international fairs, trade missions, conferences, foreign press study visits, investor study visits, and matchmaking meetings (B2B). These activities are supported by a professional advisory service and a series of specialized training in foreign trade and the registration of products in foreign markets. Scheduled events will take place in different countries, mainly in Germany, the USA, Russia, China, Switzerland and Spain. The Sector Promotion Programme for Polish Biotech & Pharma allows for a direct promotion of Polish companies and is an opportunity to obtain prospective business partners among the leading companies from the biotechnology and pharmaceutical industries. The project is implemented by a consortium of the companies Ageron Polska and Ageron Internacional, in collaboration with Bio-Tech Consulting. It would be a pleasure to assist you with any questions concerning Polish biotechnology and pharmaceutical companies. For more information please visit the programme s website: The direction of development of Polish biotechnology and pharmacy Polish biotech and pharma companies Biotechnology and pharmaceutical clusters, biotech platforms and consortia, company organizations and business support institutions Technology parks operating for pharmaceutical and biotechnology companies Science and education for the development of the biotechnology and pharmacy industry Financial support from public funds for innovative projects in the biotech and pharmacy sector Selected innovative biotech and pharmaceutical projects conducted within the framework of the Operational Programme Innovative Economy (OPIE)
3 1. The direction of development of Polish biotechnology and pharmacy Therapies based on the achievements of molecular biology and genetic engineering technology are playing an increasing role in modern medicine. The dynamic development of a new generation of biotechnological drugs and personalized medicine is possible only due to the success of life and medical sciences. The economic success of biotech and pharmaceutical companies, including those from Poland, is increasingly determined by the ability to quickly implement the results of research and by the creation of innovative products with a view, primarily, to the global market, not as previously the local one. This fact has already caused deep changes both to the mindset and functioning of the Polish scientific and (bio)business environment. Despite the fact that therapies based on biotechnological drugs are increasingly implemented in practice, apart from recombinant insulin produced by the Bioton company, no modern biotechnological drug is produced in Poland. This situation is slowly changing and, gradually, both biotech companies (MABION S.A. is the leader in this group) and large pharmaceutical companies (e.g. ZF POLPHARMA S.A.) are beginning to implement technology for biosimilars production. It is to be expected that, because of the size of the Polish drug market (sale value is estimated at about 30 billion PLN a year) and the availability of resources necessary for the development of this drug sector (see: chapters 5 and 6), biosimilars are one of the main focuses for development of the Polish biotech and pharma industry. Moreover, there are an increasing number of biotechnological drugs whose patent protection is expiring. Technology for the production of biotechnological drugs is much more advanced and requires more qualifications than the technology Increasing engagement of financial circles in the development of Polish biotech and pharma sector is a tendency, which will certainly intensify in the next years. for the production of classic generic drugs. Mastering this technology is one of the first and most important steps to be taken before undertaking the more ambitious task facing the Polish biotech and pharma industry developing new innovative biotechnological drugs and introducing them into the market. There is a clear tendency to leave behind the previous business model, consisting of the production of generic drugs, and to start working on new innovative drugs. This tendency is visible both in the case of companies producing traditional generic drugs (Adamed Group, Celon Pharma Sp. z o.o.) and also when it comes to the newly-established companies whose work combines some elements of biotechnology and pharmacy (Selvita S.A., Blirt S.A., Celther POLSKA Sp. z o.o., Stem Cells Spin S.A., Proteon Pharmaceuticals S.A.). These companies work on producing new drugs with a view to the global market. The motto Polish biotech and pharma go global is the strategic direction for an increasing group of young dynamic companies from the biotech and pharma industry. 1 Despite the fact that the number of biotechnological companies in Poland is still low (about 70), the sector is growing dynamically. Over half of the companies have been established in the last 5 years. Nevertheless, the real boom for biotech startup companies is still ahead. A high number of scientific teams conducting biotechnological R&D projects, systematically developed infrastructure necessary for the functioning of such companies (incubators, technology parks), qualified personnel (see chapter 5), increased interest in application research, including raised awareness of the importance of proper patent protection for research results among Polish scientists all of these create good conditions for establishing innovative startup companies. The development of the biotech and pharma sector stimulates the possibility of obtaining funds for innovative products, both from European Union funds and financial instruments created by the Polish government (e.g. by such institutions as the National Center for Research and Development, Polish Agency for Enterprise Development, National Capital Fund). Nevertheless, the influence of private investors, both individual and institutional (e.g. venture capital funds) is equally important for its success and dynamics. Investors have already noticed the potential of the industry, which is indicated, for example, by the valuation of biotech companies listed on the Warsaw NewConnect stock exchange market. The increasing engagement of financial circles in the development of the Polish biotech and pharma sector is a tendency, which will certainly intensify in the future years. This tendency will be the most objective indicator of the sector s development and potential.
4 2. Polish biotech and pharma companies Currently there are about 70 biotechnology companies (figure 2.1) and over 140 pharmaceutical companies (figure 2.2) in Poland. An interesting group of biotechnology companies are the so-called core biotech companies. These companies focus their activity mainly on developing new innovative biotechnology products. R&D represents at least 50% of their total activity. These companies use recombinant DNA technology, modern technologies of molecular biology, cell biology and tissue engineering in developing new technologies. They constitute still a small (15% of the total number of biotech companies in Poland), but very dynamic group with great development potential. 2 The vast majority of Polish biotech companies work on new innovative products, which are at different implementation stages. Innovative drugs constitute the majority of these products (figure 2.3), both biosimilars and new original biotechnology drugs. A significant number of companies from this sector operate through combining some elements of biotechnology and traditional pharmacy (e.g. Adamed or Celon Pharma). They produce traditional generic drugs and conduct research on new original biotechnology drugs. An interesting group of biotechnology companies are the so-called core biotech companies. R&D represents at least 50% of their total activity. Polish producers of generic drugs also realize the importance of biotechnology for the development of modern innovative biopharmacy. ZF Polpharma S.A., the largest Polish company producing generic drugs can serve as a good example. It has created a special research and development department, Polpharma BiologicS, whose main task is to develop both original biotechnology drugs and biosimilars, implement their production and introduce them into the market. What is characteristic of both Polish biotech companies and generic drug producers is their openness to cooperation with foreign partners. Work on innovative drugs and/or new generations of already existing drugs with market authorization stimulate Polish companies to implement new technologies for production on an industrial scale. Mabion S.A. is an example of a biotechnology company implementing the production of biotechnology drugs humanized monoclonal antibodies used in tumor treatment. The company implements technology of production of recombinant proteins using modern orbital shake bioreactors. The technology has been used mainly in modern research and development laboratories. Mabion will be one of the first companies in the world to use it in industrial production. What is characteristic of both Polish biotech companies and generic drug producers is their openness towards cooperation with foreign partners. Polish companies actively participate in international events (CPhI, BioConvention) and co-created BioForum ( a Central European cooperation platform for biotech and pharma companies.
5 Warszawa+ Kraków Wrocław Gdańsk, Gdynia Figure 2.1. Biotech companies in Poland. Poznań Łódź Other Pharma manufacturers Foreign subsidiaries Distributors Figure 2.2. Pharma companies in Poland. 0% 5% 10% 15% 20% 25% New cosmetics 23% Drugs for metabolic dis. 21% Oncology drugs 16% Food supplements 12% Immunology drugs 8% API Neurodegenerative dis. drugs 5% 5% Molecular biology tools 3% Other 7% Figure 2.3. The main groups of innovative products to be implemented by the Polish biotech companies in
6 3. Biotechnology and pharmaceutical clusters, biotech platforms and consortia, company organizations and business support institutions 3 Nutribiomed Cluster Office: Wroclaw Technology Park S.A. Klecinska Wroclaw Phone: klaster@nutribiomed.pl The cluster was created by 17 companies and 3 Wrocław universities (Wrocław University of Environmental and Life Sciences, Wrocław Medical University and University of Wrocław). Currently, the cluster gathers together 40 entities including 6 higher education schools, 3 business support institutions and 31 companies. The primary task of the cluster is to develop new dietary supplements, nutraceuticals and biomedical preparations based on native natural resources and on its own know-how. The following companies and institutions are among the cluster members: - University of Wrocław - Wrocław Technology Park S.A. - Wrocław Medical Science and Technology Park - Wrocław University of Environmental and Life Sciences - Poznań University of Life Sciences - Chem In - GALENA FSP - Algae Labs - Finepharm S.A. - Biochefa FZNP - BIOXEN Sp. z o.o. LifeScience Cluster Kraków Office: Bobrzynskiego Krakow Phone: klaster@lifescience.pl The cluster was created at the initiative of the Jagiellonian University in Kraków in October Its primary aim is to support initiatives and innovations in the life science field and create conditions for effective commercialization of the results of research and development work. Administered by the Jagiellonian Centre of Innovation Sp. z o.o., the cluster embraces 32 institutions, including biotech companies and healthcare companies. The cluster members include: - Apipol-Farma Sp. z o.o. - Bio Byte - Biospekt Sp. z o.o. - Bio Te 21 Adam Master - Diagnostyka Sp. z o.o. - FARMINA Sp. z o.o. - BIOMED S.A. Instytut Biotechnologii Surowic i Szczepionek - Institute of Pharmacology of the Polish Academy of Sciences - Jagiellonian Center of Innovation Sp. z o.o. - JCI Venture - Krakow Cardiovascular Research Institute Sp. z o.o. - Laboratoria.net - Microbiolab - Oncogene Diagnostics Sp. z o.o. - Tadeusz Kościuszko Kraków University of Technology - Selvita S.A. - Trigendo Sp. z o.o. - Jagiellonian University - University of Agriculture in Kraków
7 Polish Technology Platform for Innovative Medicine (PPTIM) Polska Platforma Technologiczna Innowacyjnej Medycyny (PPTIM) Wolska Warszawa Phone: The Polish Technology Platform embraces companies conducting and funding research to develop new drugs, medical technologies, medical equipment modernization and the development of innovations in medicine. Its primary aim is to develop innovative pharmacy and increase the competitiveness of the Polish pharmaceutical industry. The following companies are the members of the Polish Technology Platform: - ADAMED GROUP - Biocentrum Sp. z o.o. - BioContract Sp. z o.o. - Biofarm Sp. z o.o. - Biomed Sp. z o.o. Wytwórnia Surowic i Szczepionek - Biowet Puławy Sp. z o.o. - Galena FSP - BIOMED S.A. Instytut Biotechnologii Surowic i Szczepionek - LABOFARM - Jelfa S.A. - Krzysztof Kucharczyk Electrophoretic Techniques Sp. z o.o. - Laboratory of Molecular Genetics - Novasome Sp. z o.o. - Read Gene S.A. - Selvita Sp. z o.o. - Synteza Sp. z o.o. - Vipharm S.A. - Wekz Med Sp. z o.o. - Polish National Contact Point for Research Programmes of the European Union - ZF Polpharma S.A. 3 BioTechMed Advanced Technology Centre Biuro Organizacyjno-Koordynacyjne CZT BioTechMed Politechnika Lodzka Stefanowskiego 1/ Lodz Phone: agata.kaczorowska@p.lodz.pl The BioTechMed Consortium conducts projects within the fields of: - medical biology, chemical biology, medical chemistry, virology - life sciences, biotechnology - materials science and materials engineering - pharmaceutical sciences, nonoperating clinical sciences, molecular and cell biology - techniques in medicine, biomedical engineering - chemical technology; chemistry, chemical sciences - crop and soil science The BioTechMed is a consortium of companies and scientific institutions from the region of Łódź, constituting the Advanced Technology Center together conducting research and development in the field of healthcare and protection of the natural environment, using the achievements of biotechnology, technology and medical sciences. The consortium has the following members: - Molecular and Macromolecular Research Center of the Polish Academy of Sciences - Institute for Medical Biology of the Polish Academy of Sciences - Nofer Institute of Occupational Medicine - Technical University of Łódź - University of Łódź - Medical University in Łódź - Polfarmex S.A. - IFOTAM Sp. z o.o. - BTL Sp. z o.o. Zakład Enzymów i Peptonów - Pharmena Sp. z o.o. - ICHEM Sp. z o.o. - Non-Public Health and Care Center Allergology Center - GASTRO Health and Care Center Consultative Clinic - International Institute of the Polish Academy of Sciences the European Regional Center on Ecohydrology under the auspices of UNESCO - Łódź Regional Park of Science and Technology Sp. z o.o.
8 3 Biocentrum Ochota Consortium Biocentrum Ochota Instytut Medycyny Doswiadczalnej i Klinicznej im. M. Mossakowskiego PAN Pawinskiego Warszawa Phone: sekretariat@cmdik.pan.pl Biocentrum Ochota is a consortium of academic institutions of the Polish Academy of Sciences. It embraces: 1. Institute of Biochemistry and Biophysics of the Polish Academy of Sciences 2. Nałęcz Institute of Biocybernetics and Biomedical Engineering of the Polish Academy of Sciences 3. Nencki Institute of Experimental Biology of the Polish Academy of Sciences 4. Mossakowski Medical Research Center of the Polish Academy of Sciences 5. Institute of Fundamental Technological Research of the Polish Academy of Sciences 6. International Institute of Molecular and Cell Biology The consortium conducts research within the following fields: - molecular biology of molecular chaperones - biosensors and microsystems for multiparameter biochemical analysis - mitochondrial protein biogenesis - methods of visualization and analysis of processes in the living cells populations for diagnostics and therapy - structural studies of nucleus acid enzymes - hybrid systems for the production of biological factors - role of the cell cortex mechanics in cell mobility - reconstruction and regeneration of tissues for biomedical applications - molecular development mechanisms of dendritic arbor of neurons - crystallographic research on eukaryotic methylases - role of endocytosis in intracellular signal transduction - proteomic and genomic of neurogenerative diseases - analysis of enzymes responsible for post-transcriptional modification of RNA InnoBioBiz Cluster Łódź Coordinator: Mikołaj Gurdała Biuro Analiz i Strategii Uniwersytetu Medycznego w Lodzi Kosciuszki Lodz mikolaj.gurdala@umed.lodz.pl The cluster was created by Łódź biotechnology companies and business support institutions in December The Medical University in Łódź and the University of Łódź are among the members of the cluster as well. The main goal of this cluster is to create conditions for the development and promotion of innovative biobusiness in the region, based mainly on the innovative biotech companies. The cluster gathers together the following companies and institutions: - Mabion S.A. - Celther Polska Sp. z o.o. - Proteon Pharmaceuticals S.A. - Flavopharma Sp. z o.o. - Bio-Tech Consulting Sp. z o.o. - Bio-Tech Invest Sp. z o.o. - Hot Gene - University of Łódź - Center for Technology Transfer of the University of Łódź - Medical University in Łódź
9 Organizations gathering Polish companies from the biotech and pharmacy sector POLFARMED Polish Chamber of Pharmaceutical and Medical Devices Industry Lucka 2/4/ Warszawa Phone: Established in 1993, it gathers together companies conducting business activities within the field of: - producing medical products and devices and introducing them to the market, - producing dietary supplements, special food products as well as materials and equipment used for producing medical products and devices and introducing them to the market, - services concerning the production of medical products and devices and introducing them to the market. Polish Employer Association of Pharmaceutical Industry Wisniowa 40b/ Warszawa Phone: biuro@producencilekow.pl The organization was created in September It represents the producers of generic drugs and covers mainly large pharmaceutical companies. INFARMA Employers Union of Innovative Pharmaceutical Companies Pulawska Warszawa Phone: biuro@infarma.pl The union includes mainly branches of foreign pharmaceutical companies operating in Poland. 3 Polish Council for Supplements and Nutritional Foods Chlodna Warszawa Phone: info@krsio.org.pl Established in 2004, the organization represents the interests of producers of dietary supplements and functional food.
10 Governmental organizations supporting the development of innovative pharmacy and biotech sector Polish Agency for Enterprise Development (PARP) Panska 81/ Warszawa Phone: A government agency using funds from the state budget and European Union funds to support enterprise development, innovativeness and development of human resources. Polish Information and Foreign Investment Agency S.A. (PAIIZ) Bagatela Warszawa Phone: invest@paiz.gov.pl The agency helps foreign investors to enter the Polish market and invest in Poland. It provides comprehensive information concerning the legal environment of investments as well as help in finding proper partners and locations. 3 National Center for Research and Development (NCBR) Nowogrodzka 47a Warszawa Phone: sekretariat@ncbir.gov.pl The National Center for Research and Development is an executive agency of the Minister of Science and Higher Education. It conducts tasks within the field of science policy, science and technology policy and the innovation policy of the state. It performs the role of an intermediate body in three operational programmes: Human Capital, Innovative Economy and Infrastructure and Environment.
11 4. Technology parks operating for pharmaceutical and biotechnology companies Technology Park of the Jagiellonian Center of Innovation (JCI) LifeScience Park Bobrzynskiego Krakow Phone: jci@jci.pl The Technology Park in Kraków has a complex of 3 buildings located at Bobrzyńskiego street 14. One of the buildings, with an area of 6,780 m 2, addresses the needs of small innovative biotech companies - biotech startup companies. The other two buildings perform the role of a technology park and offer space for commercial lease for domestic and foreign companies from the life science sector. The Technology Park is managed by the Jagiellonian Center of Innovation Sp. z o.o. (JCI), which is owned by the Jagiellonian University in Kraków. The company administers the activity of LifeScience Cluster as well. Within the framework of the JCI group there is also the JCI Venture Sp. z o.o. investment fund, which invests in biotech projects, including startup companies. The investment portfolio of the fund currently consists of 6 innovative companies from Life Science sector. Wrocław Research Center EIT+ (WRC EIT+) Wroclaw Research Center EIT+ Sp. z o.o. Stablowicka Wroclaw Phone: biuro@eitplus.pl Wrocław Research Center EIT+ conducts activity exceeding the traditional formula of a technology park. Just as in the case of typical technology parks, it offers infrastructure to innovative companies, including biotech companies. WRC EIT+ creates and develops such biotechnology laboratories, as the following: - Laboratory for structural analysis - Laboratory for molecular modelling - Laboratory for immunochemistry, pathogens, molecular microbiology - Laboratory for syntheses of new materials - Laboratory for cellular imaging - Laboratory for bacteriological bases, culture fluids - Laboratory for bionanotechnology - Laboratory for target drug delivery - Laboratory for modulation of RNA catalytic activity - Laboratory for biomarkers - Laboratory for diagnostics of cancer diseases - Specialist biotechnological laboratory One important activity of the WRC EIT+ concerns research and development projects in the fields of: nanotechnologies, biotechnology and medicine, climate and energy, information and communication technology. Research conducted in the field of biotechnology and medicine aims to develop innovative anti-carcinogenic and anti-osteoporosis drugs, develop new methods for identifying hallucinogenic substances, methods for diagnostics and prevention of bacterial diseases, search for new biodegradable polymers such as drug carriers, obtain a new generation of vaccines and antibiotics based on new chemical compounds. Within the framework of the Accelerator EIT+ the WRC EIT+ creates innovative spin-off companies. Lipid System Sp. z o.o. can serve as an example of an innovative spin-off pharmaceutical company. In cooperation with the Medical University in Wrocław, the EIT+ is creating the Biobank in gathering biological material used for research, mainly blood samples, as well as DNA samples, tissues, and cell lines. 4
12 Wrocław Technology Park Wroclaw Technology Park Muchoborska Wroclaw Phone: The park offers lab space for lease for biotechnology companies. Creating innovative products based on the MIC-1 stem cells, Stem Cells Spin is one of the biotech companies whose research and production laboratory is located in the park. The Lower Silesian Academic Incubator for Entrepreneurship is one of the institutions operating within the framework of the park. Six years of the Incubator s activity resulted in 60 newly-established innovative companies created or co-created by Wrocław scientific circles. The park has its own laboratory rendering research services in the field of chemistry and biotechnology. Poznań Science and Technology Park Adam Mickiewicz University Foundation in Poznan - Poznan Science and Technology Park Rubiez Poznan Phone: ppnt@ppnt.poznan.pl High Technology Incubators operating within the framework of the Poznań Science and Technology Park offer lab spaces tailored to the needs of biotech research and development projects. A microbiology service lab and a processing room with an area of 164 m 2, are created there as well. The following biotech companies are among the entities operating in the Poznań Science and Technology Park: CB DNA Sp. z o.o. - a company conducting molecular diagnostics and Future Synthesis - molecular probe synthesis, DNA/RNA synthesis. 4 Nickel Technology Park Poznań (NTPP) Nickel Technology Park Poznan Sp. z o.o. Krzemowa 1, Zlotniki Suchy Las Phone: biuro@ntpp.pl The NTPP is a private technology park offering office, lab and storage spaces for innovative companies. Within the framework of the so-called Business Development Area, young companies and businessmen who are just starting up obtain preferential terms for the leasing office space. With the help of the Nickel Incubator which operates within the technology park, it is possible to obtain financial support for innovative business projects. The Nickel BioCentrum project, aimed at biotech companies, was launched in It is a modern building with lab spaces for biotechnology companies operating in the Bio/Med sector. The multi-faceted architecture of the lab space designated for lease allows a company to adapt it according to the needs arising from the current stage of its development. Gdańsk Science and Technology Park (GPN-T) Prof. Hilary Koprowski Gdansk Science and Technology Park Trzy Lipy Gdansk Phone: office@gpnt.pl A technology incubator operating within the framework of the park supports the establishment and development of innovative startup companies. The park offers specialist laboratories, as well as infrastructure for launching modern processing rooms, including those for the production of biotech and pharmacy products. Well-known Polish pharmaceutical and biotech companies have their laboratories in the area of the park, including ZF Polpharma S.A., Blirt S.A., Biomax S.A., Lipopharm.PL
13 Pomeranian Science and Technology Park (PPNT) Pomorski Park Naukowo- Technologiczny (PPNT) Zwyciestwa 96/ Gdynia Phone: The park is administered by the Gdynia Innovation Center. Biotechnology and pharmaceutical companies operating on the area of the park include A&A Biotechnology, Cerko PPHU s.c., Immunolab Sp. z o.o., Phage Consultants, Prochimia Surfaces Sp. z o.o., Spark-Lab s.c., TCI Laboratories. The park offers office and lab space fulfilling the requirements and expectations of biotech companies. Supporting the development of highly advanced technologies, including biotech companies, is one of the main tasks of the park. TechnoPark Lodz Lodz Regional Park of Science and Technology Sp. z o.o. Dubois 114/ Lodz Phone: biuro@technopark.lodz.pl The modern building of the TechnoPark offers office and laboratory spaces designed especially for the incubation of biotech startup companies. A research and implementation center for biotechnology and nanotechnology is being created. The park offers a wide range of lab and research services based on its own laboratories equipped with modern devices and scientific apparatus. The range of research offered covers: - biofuels - new biomaterials and biotechnologies - probiotics and prebiotics - wastewater treatment enzymes - technologies for microbial biodegradation of pollutants - preparations for microbial biodegradation of environmentally toxic substances - technologies of in-situ biogasification of lignite seams 4
14 5. Science and education for the development of the biotechnology and pharmacy industry There are over 8,000 biotechnology students attending 36 Polish higher education schools. There are over 8,000 biotechnology students attending 36 Polish higher education schools. The number of graduates (fig. 5.2) is much higher than the employment opportunities offered by Polish biotech and pharma companies. About 30,000 students graduate in life science in Poland every year. The subjects of biotechnology and pharmacy are being developed in almost all the larger academic centers in Poland (fig. 5.3). Leading centers are located in such academic cities as: Kraków, Wrocław, Poznań, Łódź, Warsaw and Gdańsk. Working at the universities and institutes of the Polish Academy of Sciences, over 2,800 scientists specializing in life and medical sciences constitute the scientific potential of biotechnology and pharmacy in Poland. Research and development projects of the biotech and pharma industry are conducted in over 100 scientific institutions. Most ongoing research and development projects in Poland (over 70% of all biotechnology R&D projects) concern the development of innovative products, which can be applied in health care. The subjects and percentage of particular types of R&D projects conducted in Poland are presented in fig Most ongoing research and development projects in Poland (over 70% of all biotechnology R&D projects) concern the development of innovative products, which can be applied in health care. 20% 5 9% 15% 18% 38% Fig Type of current biotechnology R&D projects in Poland. Drugs Medical materials Diagnostic kits Molecular biology tools Other Graduates with Master of Science degree Graduates with Bachelor of Science degree Fig Graduates in biotechnology ( ).
15 Gdańsk, Gdynia Szczecin Bydgoszcz Olsztyn Poznań Warszawa Łódź Lublin Wrocław Katowice Kraków Rzeszów Fig The most important academic centres conducting research and development projects in the field of biotechnology and pharmacy. 5
16 6. Financial support from public funds for innovative projects in the biotech and pharmacy sector The Operational Programme Innovative Economy (OPIE) is one of the main financial sources for innovative research and development for investment projects in the pharmacy and biotech industry. The value of current projects conducted within the framework of the programme by Polish biotech and pharmaceutical companies exceeds 1.28 billion PLN (about million EUR). Over 40% of the sum is covered by public funds within the framework of the Operational Programme Innovative Economy (fig. 6.1). 41% Costs incurred by companies (approx million PLN million EUR) 59% External funding for innovative projects covered by public means within the OPIE (approx million PLN million EUR) Figure 6.1. Expenditure (in PLN) for innovative projects conducted by Polish biotech and pharmaceutical companies. The value of ongoing innovative biotech and pharmaceutical R&D projects conducted by Polish scientific institutions is slightly higher than in the case of companies and exceeds 1.35 billion PLN (about million EUR). The share of public funds (total sum amounts to about 1.27 billion PLN million EUR) in financing R&D projects conducted by scientific institutions is significantly higher than in the case of companies (fig. 6.2). As much as 85% of the total external funding is covered by the means (grants) from the European Union. The value of ongoing innovative biotech and pharmaceutical R&D projects conducted by the Polish scientific institutions is slightly higher than in the case of companies and exceeds 1.35 billion PLN (about million EUR). 6 6% Costs incurred by research institutes (approx. 80 million PLN million EUR) Funding through public means (approx billion PLN million EUR) 94% Figure 6.2. Expenditures (in PLN) for innovative research and development projects conducted by Polish scientific institutions.
17 7. Selected innovative biotech and pharmaceutical projects conducted within the framework of the Operational Programme Innovative Economy (OPIE) 1. POIG /08-04 Project title: 3CLA - biotechnology anticancer medicine Company: Adamed GROUP OPIE contribution: PLN Description: This is a project from the field of medical biotechnology. The therapeutic molecule the project focuses on is an anticancer protein equipped in a special system which targets the tumor cells. The key task of the project is to develop an optimum form of active molecules, which will provide both maximum therapeutic activity and stability. Pilot-plant scale optimization of synthesis and purification is planned, which will be the next step before conducting the research necessary for the drug candidate to enter the clinical trial and, subsequently, undergo the trial. Innovativeness of the project consists mainly in using an original scientific concept as the basis for rational design of structures of the prospective drugs with desired physical, chemical and biological features. 2. POIG /09-02 Project title: Innovative compounds with highly selective toxicity as prospective drugs of crucial importance for the market of antifungal agents Company: Blirt S.A. OPIE contribution: PLN Description: The project aims to develop a new biologically active compound with the features of a prospective innovative drug, which could be used in the treatment of systemic mycoses. A positive result from the project will be a breakthrough in the treatment of systemic mycoses. The implementation consists of developing the technology and obtaining the data necessary for increasing the scale of prospective drug production. The innovativeness of the project consists mainly in using an original scientific concept as the basis for the rational design of the structures of the prospective drugs with desired physical, chemical and biological features (innovative approach, especially in the case of antifungal drugs). 3. POIG /09-02 Project title: Innovative drug used in treating tumor diseases, impeding activity of STAT3 transcription factor Company: Celon Pharma Sp. z o.o. OPIE contribution: PLN Description: The project aims to develop a new drug to be used in anticancer treatment. Currently, the drug is at the stage of pre-clinical development. For now, the research results have confirmed the effectiveness of the molecule. In the near future, animal testing starts, which will ultimately verify the therapeutical and pharmacological features of the drug. 7
18 4. POIG /08-04 Project title: Package of innovative biopharmaceuticals for human and animal therapy and prophylactics Scientific institution: Institute of Biotechnology and Antibiotics OPIE contribution: PLN Description: The project consists of creating the Centre for Medicinal Product Biotechnology in a branch of the Institute of Biotechnology and Antibiotics in Macierzysz near Warsaw. The project falls in line with the Health research area presented in the National Framework Programme. The priority research directions in this field include 1.3 Molecular biology and biotechnology and their influence on improving the health and quality of life of society and 1.6 Innovative and generic drugs, materials and support equipment for diagnostics and medical therapy. 5. POIG /09-07 Project title: Establishing a research and development center for genetic research of cancer Company: READ-GENE S.A. OPIE contribution: PLN Description: The direct aim of the project is to establish a research and development center, which will conduct genetic research and development work concerning cancer diagnostics and prevention. The strategic goal of the investment planned by the READ-GENE S.A. is the commercialization of methods for the detection, prevention and treatment of the most common types of cancer. As a result of research and development work conducted in the field of cancer genetics, new products will be introduced into the market genetic tests, dietary supplements and new drug formulas preventing the most popular forms of cancer, i.e. breast cancer, ovarian cancer, colorectal cancer and prostate cancer. 6. POIG /09-04 Project title: Peptaderm Development of a new drug based on truncated analog of cyclolinopeptide A (cyclic tetrapeptide) Company: Peptaderm Sp. z o.o. OPIE contribution: PLN 7 Description: The aim of the project is to develop technology for obtaining medicinal means and introducing them into the market. The project is based on a molecule, which is an innovative chemical compound of immunosuppressive and antiphlogistic features to be used in dermatology. The first animal tests suggest the possibility of using the chemical compound in the production of topical drugs (cream, ointment) in allergic and seborrhoeic skin diseases, such as atopic dermatitis, psoriasis, different types of eczema, seborrhoeic dermatitis, skin T-cell lymphoma, photoallergic skin changes, skin drug reactions. Generally, it seems that the molecule, because of its strong antiphlogistic effects, can be used in all the cases where nowadays steroids are used, but without their side effects. Because of its low toxicity, the drug seems to be safe for children. Generally, it seems that the molecule, because of its strong antiphlogistic effects, can be used in all the cases which nowadays use steroids, but without their side effects.
19 7. POIG /09-03 Project title: Development of the research and development activity of the Biofana Center for Pharmaceutical Research and Clinical Trials Company: Biofana Sp. z o.o. OPIE contribution: PLN Description: The aim of the project is to create the Center for Pharmaceutical Research and Clinical Trials in the Biofana Sp. z o.o. Pharmaceutical research and clinical trials verify the influence of a drug or medical product and determine its approval on the market. Tests proving the safety and effectiveness of a new medical substance have become a part of the activity of the Biofana Center for Pharmaceutical Research and Clinical Trials, which will develop its R&D work thanks to EU funding. The center is adapting a new area for laboratories and equipping them with new specialist devices for analytical laboratories and a formulation laboratory. The project will result in extending the company s offer: introducing new research methods into the market, e.g. analysis of the contamination level in medical substances and products with the use of liquid chromatography mass spectrometry. The company will also gain the possibility of checking the identity, purity and content of active ingredients in medical products. 8. POIG /10-01 Project title: Innovative biodegradable living bandage for chronic wounds and ulcerations Company: CELTHER POLSKA Sp. z o.o. OPIE contribution: PLN Description: The project aims at developing a modern specialist biodegradable bandage and its commercial implementation. The bandage significantly accelerates the healing of wounds. 9. POIG /11-00 Project title: Development and implementation of innovative tests from the field of veterinary genetics of selected species Company: CB DNA Sp. z o.o. OPIE contribution: PLN Description: The aim of the project is to develop and implement innovative comprehensive genetic tests for veterinary diagnostics within the scope of: - identification of relationship by selected farm animals - identification of gene mutations determining genetic diseases by selected farm animals. 10. POIG /09-02 Project title: Innovative technology for producing therapeutic monoclonal antibodies used in lymphoma treatment Company: MABION S.A. OPIE contribution: PLN Description: The aim of the project is to implement an innovative system for producing therapeutic monoclonal antibodies used in the treatment of lymphoma. The system will use orbital shaker technology on an industrial scale. The technology planned for development is not a global standard for producing biotechnological products (recombinant proteins). Similar technology is used in research and laboratory work in the world, which is described in international specialized press, nevertheless, there are no known cases of the commercial production of medical products using this technology. The accomplishment of the project will introduce a new element to the production processes used currently by the company and will provide a new quality of technological processes and production capacity of biotechnological drugs. 7
20 Explore our potential! BIOTECH & PHARMA
POLISH INFORMATION AND FOREIGN INVESTMENT AGENCY PHARMACEUTICAL AND BIOTECHNOLOGICAL SECTOR IN POLAND
POLISH INFORMATION AND FOREIGN INVESTMENT AGENCY Foto: Alexander Raths Fotolia.com PHARMACEUTICAL AND BIOTECHNOLOGICAL SECTOR IN POLAND Pharmaceutical sector worldwide, further growth prospects The current
More informationPOLISH INFORMATION AND FOREIGN INVESTMENT AGENCY R&D SECTOR IN POLAND
POLISH INFORMATION AND FOREIGN INVESTMENT AGENCY Foto: AA+W Fotolia.com R&D SECTOR IN POLAND The R&D sector in Poland characteristics and possibilities of support Characteristics of the Polish economy
More informationImportance. of the pharmaceutical industry for Polish economy
Polski Związek Pracodawców Przemysłu Farmaceutycznego october 2011 Importance of the pharmaceutical industry for Polish economy The domestic pharmaceutical industry plays an important role in the Polish
More informationFACULTY OF MEDICAL SCIENCE
Doctor of Philosophy Program in Microbiology FACULTY OF MEDICAL SCIENCE Naresuan University 171 Doctor of Philosophy Program in Microbiology The time is critical now for graduate education and research
More informationMasters Learning mode (Форма обучения)
Program Title (Название программы): Pharmacology Degree (Степень) Masters Learning mode (Форма обучения) Full-time and part-time Duration of study (Продолжительность программы) 2 years (4 years part time)
More informationMolecular Biotechnology Master s Degree Program
> APPLIED LIFE SCIENCES Master s Degree Program: > FULL TIME Molecular Biotechnology Master s Degree Program www.fh-campuswien.ac.at My Occupational Future. Your Career Opportunities Biotechnology is one
More informationValentina Gualato, Ph.D. Process Development Scientist
COMPANY PRESENTATION Quality and Innovation Valentina Gualato, Ph.D. Process Development Scientist MISSION areta international is a biotech company dedicated to the contract development and manufacturing
More informationFor additional information on the program, see the current university catalog.
For information call: Tel: (818) 77-81 Fax: (818) 77-08 E-mail: chemistry.office@csun.edu Website: http://www.csun.edu/chemistry Or write: Department of Chemistry and Biochemistry California State University,
More informationBachelor of Science in Applied Bioengineering
Bachelor of Science in Applied Bioengineering Applied bioengineering employs scientific and engineering principles to process biological materials from biological agents for provision of goods and related
More informationBiochemistry. Entrance Requirements. Requirements for Honours Programs. 148 Bishop s University 2015/2016
148 Bishop s University 2015/2016 Biochemistry The Biochemistry program at Bishop s is coordinated through an interdisciplinary committee of chemists, biochemists and biologists, providing students with
More informationFACULTY OF MEDICAL SCIENCE
Doctor of Philosophy in Biochemistry FACULTY OF MEDICAL SCIENCE Naresuan University 73 Doctor of Philosophy in Biochemistry The Biochemistry Department at Naresuan University is a leader in lower northern
More informationSantaravalley: Integrating scientific research, high-tech business and academia Prof. Vladas Algirdas Bumelis President of Santara valley Association Vilnius, Lithuania 2013July 18 th Santara Valley Association
More informationHow To Test For Medical Genetics
Realizacja specjalizacji w zakresie genetycznej diagnostyki laboratoryjnej. Warszawa 22 czerwca 2010. Ministerstwo Zdrowia. Current status of counselling and medical diagnostics in the public health service
More informationBIOSCIENCES COURSE TITLE AWARD
COURSE TITLE AWARD BIOSCIENCES As a Biosciences undergraduate student at the University of Westminster, you will benefit from some of the best teaching and facilities available. Our courses combine lecture,
More informationBachelor of Science in Biochemistry and Molecular Biology
Bachelor of Science in Biochemistry and Molecular Biology Biochemistry is a subject in life sciences whose objective entails understanding the Molecular Basis of life in plants and animals. It is a multi-disciplinary
More informationSIPBS Portfolio. 2012-13 Entry
SIPBS Portfolio 2012-13 Entry MSc Programmes Existing: MSc Pharmaceutical Analysis MSc Analysis of Medicines (distance learning) MSc Clinical Pharmacy New Programmes just launched for Sept 2012 entry:
More informationScience and Technology in Wrocław
Science and Technology in Wrocław Wrocław EIT+ Programme Tadeusz Luty Wrocław University of Technology 2/15 Contents European/National/Regional perspective High technology investments in Lower Silesia
More informationINDUSTRY OVERVIEW. Our business segments. (ii) Global drug development service market Preclinical drug development services
The information and statistics set out in this section and other sections of this document were extracted from different official government publications, available sources from public market research
More information1. Program Title Master of Science Program in Biochemistry (International Program)
1 Program Structure and Specification Master of Science Program in Biochemistry (International Program) Curriculum Last Revised in 2012 for Students Entering in Academic Year 2016 -----------------------------------------
More informationEudendron: an Innovative Biotech Start-up
Eudendron: an Innovative Biotech Start-up Mauro Angiolini & Fabio Zuccotto I Venti dell Innovazione, Ville Ponti - Varese, 20 Marzo 2013 Bioindustry Park S. Fumero (Ivrea) - Italy Eudendron: a Quick Description
More informationBiomedical Engineering Graduate Program in METU / ANKARA
Biomedical Engineering Graduate Program in METU / ANKARA Faculty of Engineering Institute of Applied Mathematics Informatics Institute Faculty of Arts and Sciences Electrical and Electronics and Engineering
More informationIt is worth investing here 2015-03-29 17:51:30
It is worth investing here 2015-03-29 17:51:30 2 In the Łódź voivodeship there are a lot of institutions supporting domestic and foreign investors. Among others, they include: the Regional Investors and
More informationKazan (Volga region) Federal University, Kazan, Russia Institute of Fundamental Medicine and Biology. Master s program.
Kazan (Volga region) Federal University, Kazan, Russia Institute of Fundamental Medicine and Biology Master s program Bioinformatics I. THEORETICAL BASIS The development of effective technologies of theoretical
More informationMaster of Science in Biomedical Sciences
Master of Science in Biomedical Sciences Faculty of Medicine Good health is our greatest treasure. Understanding the human body, healthy and diseased, is the stepping stone to finding tools to improving
More informationSocial determinants of the implementation of innovative biotechnology in Poland and other EU countries
BioTechnologia vol. 92(2) C pp. 141-145 C 2011 Journal of Biotechnology, Computational Biology and Bionanotechnology OPINION Social determinants of the implementation of innovative biotechnology in Poland
More informationMSc in Toxicology. Master Degree Programme
Master Degree Programme MSc in Toxicology Department of Pharmaceutical Sciences, University of Basel Swiss Centre for Applied Human Toxicology (SCAHT) Master of Science in Toxicology University of Basel
More informationAnnual Report 2007 COMMERCIAL FINANCE WWW.INGCOMFIN.PL
2007 Annual Report 2007 COMMERCIAL FINANCE WWW.INGCOMFIN.PL It is with pleasure that I present to you the Annual Report of 2007 which describes the activity of ING Commercial Finance Polska S.A. Last year
More informationBACHELOR OF SCIENCE IN MICROBIOLOGY
BACHELOR OF SCIENCE IN MICROBIOLOGY The goal of the B.S. Microbiology program at Albany College of Pharmacy and Health Sciences is to prepare graduates for employment or advanced study in fields requiring
More informationUNIVERSITY OF MARIBOR FACULTY OF CHEMISTRY AND CHEMICAL ENGINEERING INFORMATION PACKAGE / INTERNATIONAL EXCHANGE STUDENTS' GUIDE 2016/2017.
UNIVERSITY OF MARIBOR FACULTY OF CHEMISTRY AND CHEMICAL ENGINEERING INFORMATION PACKAGE / INTERNATIONAL EXCHANGE STUDENTS' GUIDE 2016/2017 Part II Information on study programmes A) General description
More information* For additional information please refer to the Graduate Handbook.
College of Arts and Sciences Master of Science (MS) in Biology Contact Information: Dr. Roberta M. Troy, Interim Head; rmtroy@mytu.tuskegee.edu; Ph.: (334) 727 8822; 725 2364 Dr. Marcia Martinez, Graduate
More informationCourse Curriculum for Master Degree in Clinical Pharmacy
Course Curriculum for Master Degree in Clinical Pharmacy The Master Degree in Clinical Pharmacy is awarded by the Faculty of Graduate studies at Jordan University of Science and Technology (JUST) upon
More informationHuman Health Sciences
Human Health Sciences WITH PLYMOUTH UNIVERSITY DISCOVER MORE If you would like to visit Plymouth and meet our staff, then why not come along to one of our open days. Human Health Sciences WITH PLYMOUTH
More informationSelvita Integrated drug discovery collaborations
Selvita Integrated drug discovery collaborations Magdalena Żabka Selvita overview Origins Polish biotechnology research company headquartered in Krakow Mission Resources We deliver comprehensive solutions
More informationMedicines for Neglected Diseases Workshop. Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia
Medicines for Neglected Diseases Workshop Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia September 11, 2010 Poverty, Many People Poor health conditions High Morbidity
More informationSTRATEGY OF OPEN JOINT-STOCK COMPANY RUSNANO UNTIL 2020
Appendix 1 to protocol APPROVED by the Board of Directors of Open Joint Stock Company RUSNANO Protocol from 20 December 2013 #27 (section I) STRATEGY OF OPEN JOINT-STOCK COMPANY RUSNANO UNTIL 2020 Moscow
More informationgrants for innovation Grants for innovation
grants for innovation Grants for innovation Innovative Economy, 2007-2013 The Operational Programme Innovative Economy, 2007-2013 (OP IE) is one of the six National Strategic Reference Framework programmes
More informationCourse Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry
Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry The Master Degree in Medical Laboratory Sciences /Clinical Biochemistry, is awarded by the Faculty of Graduate Studies
More informationLuca Romagnoli, Ph.D. Business Development Manager
Modelli innovativi di produzione per lo sviluppo di un processo altamente qualitativo di farmaci biologici Luca Romagnoli, Ph.D. Business Development Manager BIOLOGICAL DRUGS - SOURCES Monoclonal antibodies
More informationCourse Descriptions. I. Professional Courses: MSEG 7216: Introduction to Infectious Diseases (Medical Students)
Course Descriptions I. Professional Courses: MSEG 7216: Introduction to Infectious Diseases (Medical Students) This course is offered during the first semester of the second year of the MD Program. It
More informationBSc (Hons)/MSc Nutritional Sciences - SC527 (Under Review)
BSc (Hons)/MSc Nutritional Sciences - SC527 (Under Review) Specific Titles: BSc (Hons) /MSc Nutritional Sciences BSc (Hons) Nutritional Sciences (Specialisation: Dietetics) 1. Rationale and Objectives
More informationJOMO KENYATTA UNIVERSITY OF AGRICULTURE AND TECHNOLOGY.
DAY 1 HRD 2101 - COMMUNICATION SKILLS ASS. HALL SZL 2111 - HIV/AIDS ASS. HALL 7/3/2011 SMA 2220 - VECTOR ANALYSIS ASS. HALL SCH 2103 - ORGANIC CHEMISTRY ASS. HALL SCH 2201 - PHYSICAL CHEMISTRY II ASS.
More informationSACKLER SCHOOL OF GRADUATE BIOMEDICAL SCIENCES CATALOG 2015-2016 PROGRAMS OF STUDY, COURSES AND REQUIREMENTS FOR ALL GRADUATE PROGRAMS
SACKLER SCHOOL OF GRADUATE BIOMEDICAL SCIENCES CATALOG 2015-2016 PROGRAMS OF STUDY, COURSES AND REQUIREMENTS FOR ALL GRADUATE PROGRAMS Graduate Programs CELL, MOLECULAR, AND DEVELOPMENTAL BIOLOGY CLINICAL
More informationDr Alexander Henzing
Horizon 2020 Health, Demographic Change & Wellbeing EU funding, research and collaboration opportunities for 2016/17 Innovate UK funding opportunities in omics, bridging health and life sciences Dr Alexander
More informationUCF, College of Medicine BS Biotechnology MS Biotechnology/MBA Professional Science Masters Program in Biotechnology/MBA
UCF, College of Medicine BS Biotechnology MS Biotechnology/MBA Professional Science Masters Program in Biotechnology/MBA Dr. Henry Daniell Pegasus Professor & University Board of Trustee Chair Dept. Mol.
More informationInternational scientific conference on transfer of knowledge and academic entrepreneurship
Conference information no. 1 International scientific conference on transfer of knowledge and academic entrepreneurship Department of Organization and Management, Faculty of Finance and Banking of the
More informationThe Commercialization of Technology Concepts into Medical Products
The Commercialization of Technology Concepts into Medical Products Kevin J. Scanlon, Ph.D. New Zealand 2006 International BioScience Overview Pharmaceutical Industry Biotechnology Startups Investment Community
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GUIDELINE ON THE NEED FOR CARCINOGENICITY STUDIES
More informationMaster Degree in Pharmaceutical Biotechnologies
Master Degree in Pharmaceutical Biotechnologies Department of Pharmaceutical and Pharmacological Sciences University of Padova Via F. Marzolo 5, 35131 Padova 1 The purpose of the Master Degree in Pharmaceutical
More informationUndergraduate Program in Molecular Biology http://www.biology.wisc.edu/academic_programs/molecular_biology LAST REVISED October 2009
Undergraduate Program in Molecular Biology http://www.biology.wisc.edu/academic_programs/molecular_biology LAST REVISED October 2009 Molecular biology is the basic science that seeks an understanding of
More informationMolecular Biology And Biotechnology
in Molecular Biology And Biotechnology National Institute of Molecular Biology and Biotechnology College of Science University of the Philippines Diliman, Quezon City 1101 National Institute of Molecular
More informationCornell University. School of Chemical and Biomolecular Engineering. Masters of Engineering Program Course Curriculum
Cornell University School of Chemical and Biomolecular Engineering Masters of Engineering Program Course Curriculum August 2012 2 Purpose of the Program The goal of the Masters of Engineering (M. Eng.)
More informationCourse Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology
Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology The Master Degree in Medical Laboratory Sciences / Clinical Microbiology, Immunology or
More informationATIP Avenir Program 2014. Applicant s guide
ATIP Avenir Program 2014 Applicant s guide Important dates: - November 29 th 2013: deadline for the online submission, the mailing of the hard copy of the scientific project, and the letters of recommendation
More informationCollege of Pharmacy & Pharmaceutical Sciences Graduate Catalog 2015-2016
College of Pharmacy & Pharmaceutical Sciences Graduate Catalog 2015-2016 Degrees Offered Doctor of Philosophy in Experimental Therapeutics Doctor of Philosophy in Medicinal Chemistry Master of Science
More informationM.Sc. in Nano Technology with specialisation in Nano Biotechnology
M.Sc. in Nano Technology with specialisation in Nano Biotechnology Nanotechnology is all about designing, fabricating and controlling materials, components and machinery with dimensions on the nanoscale,
More informationApplication Form Main Exhibitor
Application Form Main Exhibitor Please complete in full and return by mail or register online at /application Start of space allocation: April 13, 2015 info@analytica.de, Phone +49 89 949-20381, Fax +49
More informationManufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH
Manufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH VWR enables the advancement of science by providing high-quality chemicals and services, customized to your
More informationM110.726 The Nucleus M110.727 The Cytoskeleton M340.703 Cell Structure and Dynamics
of Biochemistry and Molecular Biology 1. Master the knowledge base of current biochemistry, molecular biology, and cellular physiology Describe current knowledge in metabolic transformations conducted
More informationGRADUATE CATALOG LISTING
GRADUATE CATALOG LISTING 1 BIOINFORMATICS & COMPUTATIONAL BIOLOGY Telephone: (302) 831-0161 http://bioinformatics.udel.edu/education Faculty Listing: http://bioinformatics.udel.edu/education/faculty A.
More informationMEDICAL EDUCATION in ENGLISH. Marek Krawczyk Rector Magnificus Medical University of Warsaw
MEDICAL EDUCATION in ENGLISH Marek Krawczyk Rector Magnificus Medical University of Warsaw INTERNATIONAL EDUCATION in POLAND 29 172 foreign students in Poland from 142 countries foreign students represent
More informationMaster of Science in Biochemistry (Molecular Medicine Option).
Master of Science in Biochemistry (Molecular Medicine Option). Molecular medicine is a specialized area of medicine. Its main thrust is to understand the molecular and cellular basis of disease. Understanding
More informationGUIDELINES FOR THE REGISTRATION OF BIOLOGICAL PEST CONTROL AGENTS FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS
GUIDELINES FOR THE REGISTRATION OF BIOLOGICAL PEST CONTROL AGENTS FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS -ii- GUIDELINES ON THE REGISTRATION OF BIOLOGICAL PEST CONTROL AGENTS FOOD AND
More informationLIFE SCIENCES QUEENSLAND LIMITED (LSQ) Mario Pennisi CEO. @LSQld
LIFE SCIENCES QUEENSLAND LIMITED (LSQ) Mario Pennisi CEO @LSQld LEADING DESTINATION FOR CLINICAL RESEARCH INVESTORS IN QLD INCLUDE: LIFE SCIENCES IN QLD ~300 companies in life sciences ~$5B invested by
More informationBioForum 2012 Central European Forum of Biotechnology and Innovative BioEconomy 23rd-24th May 2012, Brno Date & Venue Date Venue
BioForum 2012 Central European Forum of Biotechnology and Innovative BioEconomy 23 rd -24 th May 2012, Brno www.cebioforum.com Author: Edyta Wodzińska Bio-Tech Consulting 1 Date & Venue Date: May 23 rd
More informationLeukemia Drug Pathway Analyzer
Brochure More information from http://www.researchandmarkets.com/reports/2673689/ Leukemia Drug Pathway Analyzer Description: Extra value: One year of free online updates included with this product There
More informationTop 500 Innovators Society building modern science-industry collaboration
Top 500 Innovators Society building modern science-industry collaboration Conference "Science for Industry: Necessity is the mother of invention: Third Networking Event dedicated to the Polish experience
More informationStudy Program Handbook Biochemistry and Cell Biology
Study Program Handbook Biochemistry and Cell Biology Bachelor of Science Jacobs University Undergraduate Handbook BCCB - Matriculation Fall 2015 Page: ii Contents 1 The Biochemistry and Cell Biology (BCCB)
More informationContents. Page 1 of 21
Programme-specific Section of the Curriculum for the MSc Programme in Biochemistry at the Faculty of Science, University of Copenhagen 2009 (Rev. 2015) Contents... 1 1 Title, affiliation and language...
More informationBachelor of Science in Pharmaceutical Sciences (BSPS) Program Overview and Internship Requirements
Bachelor of Science in Pharmaceutical Sciences (BSPS) Program Overview and Internship Requirements Pharmaceutical Sciences Applied sciences that underlie the practice of pharmacy the development, manufacture,
More informationWhite Paper CLINICAL RESEARCH IN POLAND AN INTRODUCTION
White Paper CLINICAL RESEARCH IN POLAND AN INTRODUCTION Table of Contents 1. Healthcare Landscape in Poland... 3 2. Clinical Research Activity in Poland... 3 3. References... 6 4. About the Author... 6
More informationPatent Group Life Sciences and Biotechnology
Patent Group Life Sciences and Biotechnology Life Sciences & Biotechnology BSc Hons (First Class), Imperial College, Biochemistry, 1984 PhD, University of Kent, Biochemistry, 1987 UK Chartered Patent Attorney,
More informationGraduate Certificate Pre-Med Program Course Descriptions For Year 2015-2016 FALL
Graduate Certificate Pre-Med Program Course Descriptions For Year 2015-2016 FALL COURSE TITLE: BIOCHEMISTRY COURSE NUMBER: 5104 This course emphasizes biochemical compounds, processes and systems, designed
More informationDepartment of Microbiology Vidyasagar University Midnapore - 721 102 West Bengal
S'yllabus for the I 'year FG Diploma Course in QUALITY CONTROL AND ASSURANCE IN MICROBIAL TECHNOLOGY (Semester Based: 400 marks in two semesters) Department of Microbiology Vidyasagar University Midnapore
More informationCompany Presentation
Company Presentation DISCLAIMER This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of amp biosimilars
More informationCHEMISTRY. Faculty. Programs Offered. Bachelor of Science in Chemistry (certified by the American Chemical Society) Careers in Chemistry
CHEMISTRY Department Office Darwin Hall 300 (707) 664-2119 www.sonoma.edu/chemistry Department Chair Lynn R. Cominsky Administrative Coordinator Cathi Cari-Shudde Faculty Steven Farmer Meng-Chih Su *Dale
More informationPharmacology skills for drug discovery. Why is pharmacology important?
skills for drug discovery Why is pharmacology important?, the science underlying the interaction between chemicals and living systems, emerged as a distinct discipline allied to medicine in the mid-19th
More informationBiotechnology and Life Science Marketing Services Mailing List and Data Card Order Form
C H I Cambridge Healthtech Institute s Biotechnology and Life Science Marketing Services Mailing List and Data Card Order Form Over 800,000 names segmented by scientific interest Featuring U.S and International
More informationUniversity of Medicine and Dentistry of New Jersey (UMDNJ)
University of Medicine and Dentistry of New Jersey (UMDNJ) Dual-Degree Program between the UMDNJ Graduate School of Biomedical Sciences (GSBS) And the UMDNJ School of Public Health (SPH) Leading to the:
More informationPharmacology (BCP) Pharmacology (BCP) Requirements for the Major in Pharmacology (BCP) PHARMACOLOGY (BCP) Spring 2016. Major in Pharmacology
Pharmacology (BCP) Major in Pharmacology Department of Pharmacological Sciences, College of Arts and Sciences Chairperson: Michael Frohman Director of Undergraduate Studies: Robert Watson Phone: (631)
More informationImporting pharmaceutical products to China
Importing pharmaceutical products to China Imported pharmaceutical products need pre-market approval before entering the Chinese market Imported drugs for human use are required to obtain pre-market approval
More informationUniversity undergraduate study of Cosmetology at Faculty of pharmacy: Why and how?
University undergraduate study of Cosmetology at Faculty of pharmacy: Why and how? MIRJANA GAŠPERLIN University of Ljubljana, Faculty of pharmacy, Aškerčeva 7, 1000 Ljubljana P-SC- COS member 2014 EAFP
More informationHave a Bright Idea? University of North Texas Master of Science in Environmental Science
Have a Bright Idea? University of North Texas Master of Science in Environmental Science Professional Science Master s Degree MS Environmental Science MS in Environmental Science - Proposed Professional
More informationCurriculum Policy of the Graduate School of Agricultural Science, Graduate Program
Curriculum Policy of the Graduate School of Agricultural Science, Graduate Program Agricultural Science plans to conserve natural and artificial ecosystems and its ideal of "Sustainable coexistence science"
More informationExploring Careers in Biochemistry and Molecular Biology ASBMB
Exploring Careers in Biochemistry and Molecular Biology ASBMB Table of Contents Take the Biochemistry and Molecular Biology Challenge 1 What is Biochemistry and Molecular Biology? 3 Preparing for a Career
More informationNon-clinical development of biologics
Aurigon Life Science GmbH Non-clinical development of biologics Requirements, challenges and case studies Committed to Life. Sigrid Messemer vet. med. M4 Seminar March 10 th 2014 Aurigon - your full service
More informationDegrees in Science (& Physics)
Degrees in Science (& Physics) NUI, Galway College of Science National University of Ireland, Galway Revised January 2008 3 The world has changed...it has become FLAT! Geography no longer matters. Three
More informationRecombinant DNA and Biotechnology
Recombinant DNA and Biotechnology Chapter 18 Lecture Objectives What Is Recombinant DNA? How Are New Genes Inserted into Cells? What Sources of DNA Are Used in Cloning? What Other Tools Are Used to Study
More informationAutomating Cell Biology Annual general meeting, September 7, 2015. Phase Holographic Imaging www.phiab.se
Automating Cell Biology Annual general meeting, September 7, 2015 www.phiab.se 1 PHASE HOLOGRAPHIC IMAGING (PHI) Began as a research project at Lund University, Sweden, in 2000 Founded in 2004 Sales in
More informationDirector. Waldemar Krawczyk
Director Waldemar Krawczyk Waldemar Krawczyk, born in 1959, is a graduate of the Warsaw University Faculty of Chemistry and postgraduate of Forensic Experts Studies in Szczytno. Krawczyk earned his Ph.D.
More informationBSc (Hons) Biology (Minor: Forensic Science or Marine & Coastal Environmental Science)/MSc Biology SC516 (Subject to Approval) SC516
BSc (Hons) Biology (Minor: Forensic Science or Marine & Coastal Environmental Science)/MSc Biology SC516 (Subject to Approval) SC516 1. Mission, Aims and Objectives The new BSc (Hons)/ MSc course is a
More informationBiologics Biosimilars
Biologics Biosimilars Q u e st i o n s Po l i c y S a fe t y What are biosimilars? Biosimilars are sometimes incorrectly and inappropriately called generic versions of original biological medicines. But
More informationBiotechnology Sector Report
Biotechnology Sector Report Technology Roadmap Project For the Prepared by: The information contained in this document is not warranted or guaranteed in any way and is provided "as is." Rensselaer does
More informationBIOTECHNOLOGY OPERATIONS
BIOTECHNOLOGY OPERATIONS Principles and Practices Michael J. Roy TECHNISCHE INFORMATION SBIBLIOTHEK UNIVERSITATSBIBLIOTHEK HANNOVER CRC Press TaylorStFrancis Croup Boca Raton London New York CRC Press
More informationBS in Pharmaceutical Science (BSPS) degree program University of Rhode Island
To prepare students for careers in the pharmaceutical, biotechnical, consumer product and health care industries. Types of work include laboratory, regulatory oversight, engineering, economics, marketing,
More informationMaster of Philosophy (MPhil) and Doctor of Philosophy (PhD) Programs in Life Science
CURRICULUM FOR RESEARCH POSTGRADUATE PROGRAMS Master of Philosophy (MPhil) and Doctor of Philosophy (PhD) Programs in Life Science Curriculum for Master of Philosophy (MPhil) Program in Life Science The
More informationProgramme Specification (Undergraduate) Date amended: August 2012
Programme Specification (Undergraduate) Date amended: August 2012 1. Programme Title(s) and UCAS code(s): BSc Biological Sciences C100 BSc Biological Sciences (Biochemistry) C700 BSc Biological Sciences
More informationThe ING Foundation for Polish Arts
ING COMMERCIAL FINANCE POLAND ANNUAL REPORT 2012 The ING Foundation for Polish Arts All images presented in the Annual Report belong to The ING Foundation for Polish Arts. The ING Foundation for Polish
More informationCOURSE TITLE COURSE DESCRIPTION
COURSE TITLE COURSE DESCRIPTION CH-00X CHEMISTRY EXIT INTERVIEW All graduating students are required to meet with their department chairperson/program director to finalize requirements for degree completion.
More informationThe National Centre for Biomedical Engineering Science
The How this Integrated Technology Platform has impacted the development of R&D Clusters in Galway Jacinta Thornton, PhD Executive Manager, NCBES National Centre for Biomedical Engineering g Science Mission
More informationQUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES
QUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES Why are Pharmacopoeias so important in a globalised world? Pharmacopoeias have historically provided collections of medical recipes intended to ensure accurate
More information